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The pro-inflammatory cytokine interleukin-1β (IL-1β) plays important roles in immunity
but is also implicated in autoimmune disease. The most well-established mechanism of
IL-1β secretion is via activation of the NOD-like receptor family pyrin domain containing-3
(NLRP3) inflammasome which requires an initial priming signal followed by an activating
signal. However, the precise mechanism by which the inflammasome is activated remains
unclear. The role of reactive oxygen species (ROS) in this process is contradictory, with
some studies suggesting that ROS are crucial while others describe opposite effects.
In this study, we evaluated the effects of oxidative stress on IL-1β secretion. Gout is
a disease driven solely by IL-1β secretion in response to monosodium urate (MSU)
crystals which form during periods of hyperuricemia and thus presents an opportunity
to study factors contributing to IL-1β secretion. Sera and monocytes were isolated from
patients with gout to determine whether differences in antioxidant status could explain
the susceptibility of these individuals to gout attacks. In addition, sera and monocytes
were collected from patients with chronic kidney disease (CKD) for comparison as
this condition is associated with high levels of oxidative stress and disturbances in
serum uric acid levels. There were differences in some aspects of antioxidant defenses
in gout patients and these were mainly due to higher serum uric acid. Monocytes
from gout patients were more responsive to priming, but not activation, of the NLRP3
inflammasome. However, expression of the components of the NLRP3 inflammasome
were unaffected by priming or activation of the inflammasome, nor were these expression
levels differentially regulated in gout patients. Inhibition of ROS by N-Acetyl Cysteine
inhibited TLR2-induced priming of the NLRP3 inflammasome, but had no effect on
MSU-induced activation. Together these findings demonstrate that oxidative stress only
affects priming of the NLRP3 inflammasome but does not influence activation.
Keywords: IL-1β, gout, chronic kidney disease, NLRP3 inflammasome, antioxidant capacity, redox regulation,
reactive oxygen species
INTRODUCTION
Pro-inflammatory cytokines play important roles in protecting against infection but are also
implicated in autoimmune and metabolic disease (1, 2). Prototypical pro-inflammatory cytokines
include tumor necrosis factor-α (TNFα), interleukin-6 (IL-6), and IL-1β. The resounding success
of the anti-TNF and anti-IL-6 therapies for conditions such as Rheumatoid arthritis (RA) (3, 4)
and SLE (5), respectively, has caused renewed interest in understanding how, why and when these
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potent molecules are secreted in health and disease. The
mechanism of secretion of IL-1β has been a long-standing
conundrum in the field of cytokine biology. Identification of the
NOD-like receptor family pyrin domain containing-3 (NLRP3)
inflammasome as an essential component of IL-1β processing
as first described by Martinon et al. (6) was a critical step
in elucidating the mechanism by which intracellular pro-IL-1β
is processed for subsequent secretion where it contributes to
inflammatory responses.
The NLR family pyrin domain containing 3 (NLRP3)
inflammasome is a tripartite intracellular receptor consisting
of three proteins, NLRP3, ASC, and pro-caspase-1 which
oligomerize to form a cytosolic complex. Canonical NLRP3
inflammasome activation involves two distinct signals, an initial
“priming” signal that increases transcription of pro-IL-1β and
NLRP3 followed by a second signal to induce oligomerization.
NLRP3 is activated by a wide array of stimuli, such as extracellular
ATP (7), asbestos (8), and the influenza virus (9), and is involved
in the pathogenesis of many diseases (10).
Despite decades of research on this topic, the precise
molecular mechanisms by which the inflammasome is activated
are still unclear. One hypothesis, which has been the subject
of numerous studies, is that increased oxidative stress may
be involved in this process. Oxidative stress is defined as an
imbalance between the levels of reactive oxygen species (ROS)
and the antioxidant defenses that regulate these levels. ROS
are important signaling molecules (11), but if present in very
high concentrations can damage biological molecules including
proteins, lipids, and nucleic acids (12). Perhaps unsurprisingly
then, oxidative stress has been implicated in a myriad of human
diseases (13).
Many studies have presented evidence for the involvement
of ROS, and by extension oxidative stress, in activation of
the NLRP3 inflammasome (8, 14). Furthermore, NLRP3 is
itself redox sensitive (15–18). However, the role of ROS and
oxidative stress is far from clear with many conflicting lines
of evidence and contradictory results (8, 19). This suggests
it is unlikely that there is a simple mechanistic relationship
between ROS and oligomerization of NLRP3; rather, any
such relationship is more likely to be subtle and involve
oxidative stress in its entirety rather than simply an increase
in ROS.
Although IL-1β production occurs in many inflammatory
conditions, gout is unique in that it is primarily driven by this
cytokine. Gout is caused by precipitation of uric acid from the
blood into insoluble crystals of monosodium urate (MSU) that
can accumulate in joints and activate the NLRP3 inflammasome
resulting in secretion of IL-1β. Hyperuricemia is the greatest
single risk factor for developing gout and yet intriguingly, only
about 10% of hyperuricemic individuals ever have symptoms
of gout (20, 21). Furthermore the presence of MSU crystals
within joints does not necessarily precipitate the development of
an inflammatory attack (22, 23). Clearly there are other, as yet
unknown, factors that determine whether production of IL-1β
occurs as a result of hyperuricemia.
Thus, gout presents a unique opportunity to investigate the
factors that contribute to IL-1β production, and in particular the
role of oxidative stress on this process, as uric acid has both
pro-and anti-oxidant effects depending on location and context
(24, 25). This dual and paradoxical nature of uric acid means
that long-term exposure of blood monocytes to high levels of
uric acid could result in either increased oxidative stress or a
compensatory increase in antioxidant defenses, either of which
could impact on IL-1β production (26, 27). The aims of this study
are to investigate the role of oxidative stress on IL-1β production
in primary humanmonocytes isolated from people with a history
of gout by focusing on intracellular and extracellular antioxidant
defenses rather than on the more commonly studied ROS.
Peripheral blood monocytes from these patients will be analyzed
to determine whether changes occur in the molecular machinery
involved in the production and/or processing of IL-1β in these
cells as a result of exposure to high concentrations of uric acid and
potentially altered extracellular redox state. These patients have
by definition a history of hyperuricemia, but do not have acute
inflammation at the time of blood sampling that could confound
the analyses performed.
Production of IL-1β from monocytes isolated from patients
with chronic kidney disease (CKD) or with RA will also be
studied for comparison. Oxidative stress is implicated in the
pathophysiology in both of these conditions (28, 29). CKD
patients in particular have perturbations in serum uric acid which
could alter the levels of oxidative stress. However, neither of
these disease is primarily driven by IL-1β thus providing useful
comparisons to gout.
We also measured the activity or gene expression of
antioxidant enzymes previously associated with regulation of the
inflammatory response (30, 31). SOD2 is the mitochondrial
isozyme of superoxide dismutase (SOD) and detoxifies
superoxide radicals produced by the respiratory chain in
the mitochondria (32). Thioredoxin reductase 1 (TXNRD)
reduces the oxidized form of thioredoxin to the reduced form
that reduces a wide range of proteins and, in association
with peroxiredoxins (thioredoxin peroxidase), detoxifies
hydrogen peroxide (33). Glutathione peroxidase 3 (Gpx3) is an
extracellular peroxidase that also detoxifying hydrogen peroxide,
but uses reduced glutathione as the electron donor (34) and
extracellular superoxide dismutase (ecSOD) is the extracellular
isozyme of SOD, detoxifying superoxide radicals in extracellular
spaces (35).
MATERIALS AND METHODS
Reagents
Cell culture media and fetal bovine serum (FBS) were purchased
from Sigma-Aldrich (Gillingham, UK). Penecillin/streptomycin
were purchased from Thermo Fischer Scientific (East Grinstead,
UK). MSU crystals were purchased from Invivogen (San
Diego, CA). Qiazol, QuantiTect reverse transcription kit and
QuantiFast-SYBR green PCR kit were from Qiagen (Manchester,
UK).
Isolation of Primary Human Monocytes
Monocytes were isolated from 30ml of whole blood collected
from healthy volunteers (n = 52), or patients with a history
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of gout (n = 50), CKD (n = 42), or RA (n = 36) after giving
informed written consent (NRES reference: 15/NS/0083). Gout
patients were defined as individuals who had suffered from
an inflammatory arthritic attack clinically diagnosed as gout.
Many of the gout patients were prescribed allopurinol or
benzbromarone to be used daily, or colchicine or naproxen to
use as required. CKD patients were undergoing triweekly
haemodialysis and blood was taken prior to starting
haemodialysis. RA patients were identified and recruited
from rheumatology clinics. Peripheral blood mononuclear cells
(PBMCs) were isolated from whole blood by density gradient
separation using lympholyte-H cell separation media (VH
Bio, UK). Monocytes were then isolated from the PBMCs
using CD14+ magnetic beads (Miltenyi Biotec, Woking,
UK) yielding a population of monocytes with >95% purity.
For stimulation experiments, cells were seeded at 4 × 104
cells/well in 384-well tissue culture plates and stimulated for
18 h in RPMI-1640 media supplemented with 5% (v/v) FBS and
streptomycin/penicillin (100µg/mL and 100 U/mL, respectively)
containing Pam3 +/– MSU crystals. A separate 10mL sample
of blood was collected from each donor in spray-coated silica
tubes (Becton-Dickinson, Plymouth, UK) and allowed to clot
for at least 1 h. After clotting, samples were centrifuged at 1,300
× g for 10min and serum collected and stored at −80◦C until
future use.
Primary human monocytes were also isolated from single
donor plateletphoresis residues obtained from the North London
Blood Transfusion Center (United Kingdom). PBMCs were
isolated by density gradient separation using lympholyte-H
cell separation media (VH Bio, UK) followed by isolation
of monocytes by Percoll (Sigma-Aldrich) density gradient
centrifugation (36, 37). For analysis of intracellular gene
expression and total antioxidant capacity (TAC) monocytes
were seeded at around 1.5–2.5 × 106 cells per well in 24
well-plates and preincubated for 16 h with 30 mg/dl uric acid.
Following preincubation, cells were stimulated for 6 h with or
without Pam3 (100 ng/mL) in the presence of 30 mg/dL uric
acid.
Quantification of IL-1β
IL-1β in cell supernatants was measured by ELISA using matched
anti-human IL-1β antibodies purchased from R&D systems
(Oxon, UK).
RNA Extraction, Reverse Transcription and
Absolute RT-qPCR
Depending on monocyte yield, 0.5–1.6 × 106 monocytes
were lysed in 0.5mL of Qiazol and RNA was extracted
using an RNeasy kit (Qiagen) and reverse transcribed to
cDNA using the QuantiTect reverse transcription kit (Qiagen)
according to the manufacturer’s instructions. Quantitative real-
time RT-PCR (qPCR) assays for absolute quantification of
gene expression were purchased from qStandard (London, UK).
Copy numbers for NLRP3 (NLRP3), pro-caspase-1 (CASP1),
pro-IL-1β (IL1B), ASC-1 (PYCARD), superoxide dismutase-
2 (SOD2), and thioredoxin reductase-1 (TXNRD1) were
determined by qPCR using QuantiFast SYBR green PCR kit
TABLE 1 | Forward and reverse primer sequences for genes measured by qPCR.
Gene Forward Reverse
B2M 5′-ctctctctttctggcctggag-3′ 5′-acccagacacatagcaattcag-3′
RPL32 5′-catctccttctcggcatcat-3′ 5′-accctgttgtcaatgcctct-3′
CASP1 5′-atgcctgttcctgtgatgtgg-3′ 5′-ctcttcacttcctgcccacaga-3′
IL1B 5′-gtaatgacaaaatacctgtggccttg-3′ 5′-tttgggatctacactctccagc-3′
NLRP3 5′-gagatgagccgaagtggggttc-3′ 5′-gcttctcacgtactttctgtacttct-3′
PYCARD 5′-gctaacgtgctgcgcgacat-3′ 5′-ccactcaacgtttgtgaccct-3′
SOD2 5′-aagtaccaggaggcgttgg-3′ 5′-cgtcagcttctccttaaacttgtc-3′
TXNRD1 5′-tatgggcaatttattggtcctcaca-3′ 5′-gctccaacaaccagggtcttac-3′
on a Stratagene Mx3000 thermocycler (Agilent Technologies,
UK) or a Rotorgene thermocycler (Qiagen) under the following
thermocycling program; 40 cycles of 95◦C for 15 s and 60◦C
for 30 s with an initial cycle of 95◦C for 15min. Beta-2
Microglobulin (B2M) and Ribosomal Protein L32 (RPL32)
were selected as reference genes following initial experiments
confirming their stability and were used for normalization
of gene of interest (GOI) copy numbers. Primer sequences
for all genes are shown in Table 1. Copy number for each
GOI and reference gene were calculated from a standard
curve of known copy numbers for each gene run on the
same plate. Copy numbers were normalized to B2M and
RPL32 (38).
Serum Measurements
Serum uric acid concentrations were measured using an
Amplex Red-based uric acid/uricase assay kit (ThermoFisher,
Loughborough, UK) according to the manufacturer’s
instructions. Activity of serum glutathione peroxidase
(GPx) and SOD were determined using HT glutathione
peroxidase and HT superoxide dismutase assay kits
(Trevigen, Maryland, US), respectively, according to the
manufacturer’s instructions. GPx activity was measured as
rate of NADPH decrease per minute over a 10min period.
SOD activity was measured as percentage inhibition of
the rate of WST-1 reduction per minute over a 10min
period. Total serum protein concentrations were determined
using BCA protein assay (ThermoFisher) according to the
manufacturer’s instructions and used to calculate activity per
mg protein. Serum TAC was determined using an Antioxidant
assay kit (Abnova, UK) according to the manufacturer’s
instructions.
Intracellular Total Antioxidant Capacity
For measurement of intracellular TAC capacity, monocytes were
lysed in 50–100 µL of NP40 lysis buffer (10mM Tris-HCl,
150mM NaCl, 1mM EGTA, 1% NP-40, pH 7.4). TAC was
measured as above, and normalized to the protein content of the
sample.
Measurement of ROS
ROS generation was detected using the ROS-GloTM assay
(Promega, Southampton, UK) according to the manufacturer’s
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FIGURE 1 | The priming but not activating signal is ROS-dependant in human monocytes. (A) IL-1β secretion from primary human monocytes. Cells were stimulated
for 18 h with Pam3 and MSU crystals ± NLRP3 inhibitor MCC950. Bars represent means ± standard deviation and are representative of at least three independent
experiments. (B) Primary human monocytes were stimulated for 2 h with Pam3, MSU crystals, or Pam3 + MSU at the concentrations specified and ROS measured by
ROS-GloTM assay. (C,D) Primary human monocytes were stimulated for 6 h with Pam3 (100 ng/mL) ± MSU crystals (10 mg/dL) alongside the ROS inhibitor NAC
(5–10mM). ROS levels were measured by ROS-GloTM assay (C) and IL-1β secretion was determined by ELISA (D). Cell viability was determined at the end of the
experiments shown in (C,D) by cell-titer Glo assay (E,F, respectively). Data represent means from 6 individual donors + SEM (n = 6). Significance was determined by
Kruskall-Wallis analysis comparing treated vs. untreated controls (*P < 0.05, **P < 0.01).
instructions (39). Briefly, cells were stimulated for 2 h with
Pam3, MSU, or soluble uric acid in the presence of 25µM ROS-
Glo H2O2 substrate. Stimulations were completed in serum-free
Optimem cell culture media (Gibco, ThermoFisher). After 2 h
incubation at 37◦C and 5% CO2, ROS levels were determined
following a 20min incubation with the ROS-GloTM detection
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reagent. Luminescence was measured by spectrophotometry
(Biotek Synergy HT).
N-acetyl-L-cysteine (NAC) was used in some experiments
to inhibit ROS in primary human monocytes. For these
experiments, cells were preincubated for 1 h with NAC and
then stimulated for 6 h with Pam3 ± MSU crystals. NAC
concentration was maintained during the 6 h stimulation. ROS
levels were determined by ROS-GloTM and IL-1β secretion by
ELISA.
Assessment of Cell Viability
Cell viability was assessed at the end of each experiment
using the Cell-Titer GloTM assay (Promega) according to the
manufacturer’s instructions.
Statistical Analysis
Differences between groups were assessed using non-parametric
Kruskall–Wallis one-way analysis of variance (ANOVA) followed
by Dunn’s multiple comparison test or by Mann–Whitney tests.
The level of significance was set at P < 0.05. All analyses were
conducted using GraphPad Prism version 7 (Graphpad software,
San Diego, CA).
RESULTS
The Priming, but Not the Activating, Signal
for IL-1β Production Is ROS-Dependent in
Human Monocytes
Primary human monocytes secrete IL-1β when stimulated
with TLR ligands due to activation of the transcription factor
NF-κB and subsequent increased transcription of the IL1B
gene. In contrast to macrophages, the IL-1β produced is then
secreted from monocytes via the constitutively active caspase-
1 in these cells (40). Primary human monocytes secreted IL-
1β when treated with the TLR2 ligand, Pam3, and these levels
increased substantially when cells were treated with Pam3 +
MSU (Figure 1A) via activation of the NLRP3 inflammasome,
as demonstrated by inhibition of IL-1β secretion using NLRP3
inhibitor MCC950 (41). To investigate whether ROS are involved
in IL-1β secretion, cells were treated with Pam3 –/+ crystallized
uric acid and ROS levels measured by ROS-GloTM assay.
Crystallized uric acid (MSU), but not Pam3, resulted in increased
ROS levels in these cells (Figure 1B).
The fact that MSU increased ROS in human monocytes raised
the possibility that this could be one mechanism by which
crystallized uric acid could increase susceptibility to gout attacks
by increasing the quantity of IL-1β secreted from monocytic
cells. To test this hypothesis, human monocytes were treated
with Pam3 –/+MSU in the presence of NAC which reduced the
concentration of ROS by more than 90% (Figure 1C). However,
inhibiting ROS with NAC reduced the Pam3-induced IL-1β
secretion, but had no effect on IL-1β secreted in response to
Pam3 + MSU (Figure 1D). Treatment of the cells with NAC at
concentrations of 5mM or 10mM had no effect on cell viability
(Figures 1E,F), so the changes observed in IL-1β secretion were
not due to cell death in these experiments.
FIGURE 2 | Gene expression of IL1B and SOD2 in human monocytes is
increased by TLR2 activation but unaffected by soluble uric acid. Primary
human monocytes were stimulated for 6 h with Pam3 (100 ng/mL) following an
initial exposure to culture media (RPMI) or soluble uric acid (30 mg/dL). Gene
expression of IL1B (A), SOD2 (B), and TXNRD1 (C) were quantified by qPCR.
(D) Human monocytes were stimulated as above for measurement of
intracellular total antioxidant capacity (TAC) and expressed per mg of protein.
Data represents means from 3 to 4 individual donors + SEM. Statistical
analyses were performed by Mann-Whitney tests between control and uric
acid treated samples in the presence of Pam3 (ns = not significant).
Activation of TLR2 Is Associated With
Increased Gene Expression of IL1B and
SOD2 in Human Monocytes and Is Not
Affected by Soluble Uric Acid
Given that the priming step of IL-1β production was ROS-
dependent and that soluble uric acid has known antioxidant
effects (24), we next tested whether exposure of monocytes to uric
acid influenced IL-1β gene expression in response to Pam3. As
expected, treatment with Pam3 resulted in a dramatic increase in
the expression of IL1B (Figure 2A). Expression of the antioxidant
genes SOD2 and TXNRD1 were also measured to test for any
change in antioxidant response upon stimulation. Expression of
SOD2, but not TXNRD1, was significantly increased in response
to Pam3 (Figures 2B,C). Pre-incubation of the cells with 30
mg/dL (a concentration well in excess of clinical hyperuricemia)
had no effect on the expression levels of IL1B, SOD2, or TXNRD1
(Figures 2A–C). In addition, there were no changes in the total
intracellular antioxidant capacity in response to Pam3 –/+ uric
acid (Figure 2D).
Alterations in Serum Antioxidant Capacity
of Gout Patients
Uric acid is the major antioxidant in the blood; therefore
hyperuricemia could result in alterations in the extracellular
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FIGURE 3 | Serum antioxidant capacity in gout, CKD and RA patients. Serum was isolated from whole blood of healthy controls (n = 52), gout (n = 50), CKD
(n = 42), or RA (n = 36) patients. (A) Uric acid concentration was determined using amplex-red based uric acid assays. (B) GPx and (C) SOD activities were
measured using kinetic enzyme assays. (D) TAC was measured by TAC assay kit and quantified by reference to a Trolox standard curve. Serum enzyme activities and
TAC ware expressed as activity per mg protein. Individual points represent means for 2–3 replicate measurements for each donor. Error bars represent means ± SEM
of the entire population. Significance was determined by Kruskall–Wallis analysis comparing disease vs. healthy controls (*P < 0.05, **P < 0.01, ****P < 0.0001).
redox environment that could impact on the responsiveness
of monocytes to priming and activation of the NLRP3
inflammasome. Sera from gout patients were analyzed to
determine uric acid concentration together with two of the major
extracellular antioxidant enzymes, ecSOD and Gpx3, and the
TAC. Blood samples were also collected from patients with CKD
and from patients with RA for comparison.
Gout patients had significantly greater serum uric acid
concentrations than controls, while CKD patients had lower
serum uric acid (Figure 3A). Sera from both gout and CKD
patients had significantly reduced GPx activity compared to
healthy controls (Figure 3B), and CKD patients had increased
SOD activity (Figure 3C). This could be a compensatory measure
as there were no differences in overall TAC detected between
the four patient groups (Figure 3D). No significant differences
in antioxidant capacity were detected in sera from RA patients,
so these samples were not subject to further analysis.
Monocytes From Gout Patients Secrete
Higher Levels of IL-1β in Response to
Pam3 Than Healthy Controls
Monocytes were isolated from patient blood and stimulated
in vitro with Pam3, MSU, or a combination of Pam3 and
MSU and IL-1β production measured by ELISA. Secretion
of IL-1β was significantly lower from monocytes from CKD
patients when unstimulated (Figure 4A) and when treated
with MSU (Figure 4C). Monocytes isolated from gout
patients secreted significantly greater amounts of IL-1β in
response to Pam3 compared with monocytes from healthy
controls (Figure 4B). However, there was no correlation
between the quantity of IL-1β secreted and serum uric acid
concentration (Figure 4E) even when samples were divided
into normouricaemic vs. hyperuricemic (Figure 4F). These
terms refer to clinically defined normal serum uric acid
concentration (normouricemic; ≥6.8 mg/dL) or high serum uric
acid concentration (hyperuricemic; ≤6.8 mg/dL). There were no
differences in the quantities of IL-1β secreted from monocytes
isolated from any of the groups in response to Pam3 + MSU
(Figure 4D).
Expression of Genes Coding for
Components of the NLRP3 Inflammasome
Are Unchanged in Monocytes From Gout
Patients
The expression of components of the NLRP3 inflammasome
(pro-IL-1β, NLRP3, pro-caspase-1, ASC-1; gene name
PYCARD) was measured by absolute qPCR to determine
if IL-1β production in the monocytes was determined by
expression of these genes. There were no differences in gene
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FIGURE 4 | Monocytes from gout patients secrete higher levels of IL-1β in response to Pam3, but there is no correlation between IL-1β production and serum uric
acid concentration. Monocytes were isolated from whole blood from healthy (n = 40), gout (n = 40), or CKD (n = 37) donors and stimulated for 18 h with cell culture
media (A), Pam3 (100 ng/mL) (B), MSU (10 mg/dL) (C), or a combination of MSU and Pam3 (D). IL-1β secretion was determined by ELISA. (E) Correlation of IL-1β
secretion from monocytes and serum uric acid concentration in gout patients. Each point represents means from 3 to 6 replicate measurements. (F) IL-1β secretion
from monocytes from gout patients was analyzed by grouping samples according to serum uric acid concentration. Hyperuricemia is represented by a serum uric acid
of ≥6.8 mg/dL and normouricemia by serum uric acid of ≤6.8 mg/dL. Error bars represent mean ± SEM. Individual points represent means from 3 to 6 replicate
measurements for each donor. Error bars represent means ± SEM of the entire population. Significance was determined by Kruskall-Wallis analysis comparing
disease vs. healthy controls (*P < 0.05, **P < 0.01, ***P < 0.001).
expression between the different populations of monocytes
tested (Figure 5), apart from lower levels of expression of
caspase-1 in the monocytes isolated from CKD patients
(Figure 5A). Expression of PYCARD was also lower in these
cells but did not reach statistical significance (Figure 5D).
Intriguingly, there was no correlation between expression of
IL1B in monocytes from gout patients and concentration of
IL-1β secreted from these cells in response to any stimulus
(Figures 5E,F).
Monocytes Isolated From Gout Patients
Express Higher Levels of TXNRD1 but Total
Intracellular Antioxidant Capacity Is
Unchanged
The analyses of gene expression in monocytes isolated from
gout patients did not show any difference from healthy control
monocytes. However, exposure to high concentrations of uric
acid as would occur in hyperuricemic patients, could lead
to alterations in the intracellular redox environment. To test
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FIGURE 5 | Expression of genes coding for components of the NLRP3 inflammasome are unchanged in monocytes from gout patients. cDNA was prepared from
human monocytes from healthy (n = 37), gout (n = 43), or CKD (n = 35–37) donors. Expression of CASP1 (A), IL1B (B), NLRP3 (C), and PYCARD (D) was measured
by absolute qPCR. Copy numbers were calculated using standard curves for each gene of interest and normalized to expression of the reference genes B2M and
RPL32. Individual points represent means from 2 to 3 replicate measurements for each donor and error bars represent means ± SEM. Significance was determined
by Kruskall-Wallis (*P < 0.05). Correlation of IL1B gene expression in monocytes from gout patients with IL-1β secretion in response to (E) Pam3 or (F) Pam3 + MSU
crystals. Each point represent means from 3 to 6 replicate measurements for each donor. Error bars represent mean of entire population ± SEM. Correlation
significance was determined by Spearman correlation test.
whether there are any changes in the expression of intracellular
antioxidant defenses, expression of intracellular SOD2 and
TXNRD1weremeasured in themonocytes isolated from patients,
as well as the total intracellular antioxidant capacity. There was
increased expression of TXNRD1 in the monocytes from gout
patients (Figure 6A), but no change in expression of SOD2
(Figure 6B) or of TAC (Figure 6C).
DISCUSSION
Many studies have proposed a mechanistic link between IL-
1β production and increases in ROS or oxidative stress (8,
14, 17, 42). The results of this study do not support such a
premise, at least not as a direct or indeed necessary effect in
peripheral blood monocytes. However, we cannot rule out the
possibility that increases in ROS and/or oxidative stress play
a role in IL-1β production from tissue-resident macrophages
during a gout attack. There are well-known differences in the
signaling pathways involved in the production and processing
of IL-1β between monocytes and macrophages, not least in the
absolute requirement for a second signal via ATP stimulation in
addition to TLR ligation (40). Canonical NLRP3 inflammasome
activation requires both priming and activating signals. Pam3 can
function as a priming signal via ligation of TLR2, activating NF-
κB, and inducing transcription of pro-IL-1β and NLRP3 (43).
A second signal such as MSU is required for oligomerisation
of NLRP3, ASC and pro-caspase-1 which then leads to the
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FIGURE 6 | Monocytes from gout patients express higher levels of TXNRD1 but overall total intracellular antioxidant capacity is unchanged. cDNA was prepared from
monocytes isolated from healthy (n = 37), gout (n = 43), or CKD (n = 37) donors. Expression of TXNRD1 (A) and SOD2 (B) was calculated by absolute qPCR. Copy
numbers were calculated using standard curves for each gene of interest and normalized to expression of reference genes B2M and RPL32. (C) Monocytes from
healthy (n = 9), gout (n = 13), or CKD (n = 5) donors were lysed in NP40 cell lysis buffer and intracellular TAC and protein content were measured. Individual points
represent means from 2 to 3 replicate measurements for each donor. Error bars represent means ± SEM of the entire population. Significance was determined by
Kruskall-Wallis comparing disease vs. healthy controls (*P < 0.05).
processing and secretion of IL-1β (44). The results shown
here are consistent with this canonical signaling mechanism,
with a dramatic increase in IL-1β secretion in the presence
of MSU.
Although MSU increased ROS in primary human monocytes,
this was not the mechanism by which MSU increased IL-1β
secretion from these cells as inhibiting ROS had no effect on
IL-1β secretion. Our results suggest that if oxidative stress has
any effect on IL-1β production, it is only on the priming part
of the pathway and not on activation of NLRP3, consistent
with some previous studies (45, 46) but not with others (8,
47). Firstly, inhibition of ROS using NAC inhibited Pam3-
induced IL-1β secretion but not Pam3+MSU-induced IL-1β.
Secondly, monocytes isolated from gout patients were more
responsive to Pam3, but not to Pam3+MSU where the levels
of IL-1β secreted were similar to those from healthy control
monocytes.
Our findings are in agreement with a recent study showing
increased IL-1β secretion in PBMCs from gout patients
compared to healthy donors in response to Pam3 (48). However,
in contrast to our findings, this earlier work also found increased
IL-1β secretion from PBMCs in response to Pam3+MSU (48).
These differences could be due to the use of human monocytes,
rather than PBMCs where monocytes account for about 8–10%
of the total. There is some constitutively active caspase-1 in
human monocytes which is why IL-1β is secreted in response
to Pam3 alone (40) with further cleavage of pro-caspase-1 as a
consequence of NLRP3 oligomerization.
There were no differences in gene expression of NLRP3,
PYCARD, or CASP1 in monocytes from people with gout which
was consistent with our observations that pre-incubation of
monocytes with uric acid did not influence gene expression
of IL1B or the antioxidant enzymes SOD2 or TXNRD1. This
suggests that susceptibility to gout attacks is not due to an
inherent hypersensitivity in the leukocytes of these patients nor
is there a compensatory increase in expression of SOD2 that
might reflect increased oxidative stress. There is nothing in
these data to suggest that exposure of monocytes to uric acid
which, by definition, occurs at least some of the time in people
with gout, has any effect on subsequent monocyte responses to
Pam3+MSU. This is particularly interesting given that uric acid
can increase ROS levels in many cell types including hepatocytes
(49), adipocytes (50), vascular smooth muscle cells (51), and
THP-1 monocytes (52). In addition, we also observed increases
in ROS in response to uric acid in primary human monocytes
(manuscript in revision). However, the data presented here show
that any increases in ROS that occur in response to uric acid do
not appear to be associated with changes in IL-1β expression,
processing, or secretion. A limitation of this study is that we
did not have sufficient material from the patient samples to
allow analyses of the protein levels of the components of the
NLRP3 inflammasome. Although no differences in expression
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of these genes as measured by qPCR were observed, there may
be differences in the levels of these proteins due to differences
in their translation. Further studies are required to address this
possibility.
It is interesting to note that although uric acid increased
the production of ROS in monocytes, it did not appear to
impact on the overall level of oxidative stress in the cells. In
blood from gout patients where higher levels of uric acid were
measured, there were lower levels of other antioxidants and this
may have resulted inmaintaining the overall antioxidant capacity
at appropriate levels. Blood from patients with CKD contained
significantly lower concentrations of uric acid and, similar to
previous studies, of Gpx3 (53, 54), but higher activity levels of
the antioxidant enzyme ecSOD. It is not clear whether these
different antioxidants are able to compensate for each other
in vivo, particularly as they detoxify different types of ROS. It is
interesting that there were no changes in the overall antioxidant
capacity in any of groups tested despite differences in serum
uric acid. This ability to buffer against changes in oxidative
stress points to the presence of many mechanisms that operate
in concert to control redox status and explains why changes in
serum uric acid alone is not sufficient to cause release of IL-1β
and contribute to development of gout.
There was no correlation between expression and secretion
of IL-1β either in response to Pam3 or Pam3+MSU. This
is not perhaps so surprising as it has been known for some
time that synthesis of IL-1-β is regulated by both the level of
transcription and translational efficiency (55). Previous studies
have also shown that TLR2 ligands can result in increased
synthesis and intracellular processing of IL-1β but without
significant IL-1β release and notably, this work was done in
primary human monocytes (56). It is difficult to explain why this
would be the case here, particularly in the presence ofMSUwhich
causes activation of the NLRP3 inflammasome. Further work
is necessary to determine the mechanism by which increased
expression of IL-1β fails to translate into increased secretion of
the active cytokine, with a particular focus on whether activation
of the NLRP3 inflammasome can be un-coupled from release of
IL-1β.
A striking feature of these results is the lack of correlation
between serum uric acid concentration and production of IL-1β
in monocytes from gout patients, given that hyperuricaemia is
the single greatest risk factor for gout. This relationship, or lack
thereof, was confirmed by the low serum uric acid levels in CKD
patients which had no effect on the ability of these monocytes
to respond to Pam or Pam3+MSU. Previous studies have shown
that leukocytes from patients with CKD are hyporesponsive in
terms of cytokine secretion (57) and we did observe less IL-1β
secretion from the cells isolated fromCKD patients here, but only
in basal (unstimulated) conditions and in response toMSU alone.
The only difference in production of IL-1β was in the
monocytes from gout patients in response to Pam3. However,
this phenomenon also appears to be independent of exposure of
these cells to uric acid. Therefore, there must be additional, as yet
unknown, factors that regulate the production of IL-1β that are
independent of intercellular or extracellular antioxidant status.
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